SuperworthKeros Therapeutics shares outstanding KROS
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 19.8M
- On a year earlier
- −51.2%
- fewer shares
Keros Therapeutics had 19.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 51.2% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 27.2M | −33% |
| FY2024 | 40.3M | +34% |
| FY2023 | 30.1M | +10% |
| FY2022 | 27.3M | +17% |
| FY2021 | 23.4M | +8% |
| FY2020 | 21.6M | +795% |
| FY2019 | 2.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 19.8M | −51% | |
| Q1 FY26 | 19.6M | −52% | |
| Q4 FY25 | 27.2M | −33% | |
| Q3 FY25 | 40.6M | +8% | |
| Q2 FY25 | 40.6M | +12% | |
| Q1 FY25 | 41M | +15% | |
| Q4 FY24 | 40.3M | +34% | |
| Q3 FY24 | 37.6M | +27% | |
| Q2 FY24 | 36.1M | +22% | |
| Q1 FY24 | 35.7M | +26% | |
| Q4 FY23 | 30.1M | +10% | |
| Q3 FY23 | 29.7M | +16% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Keros Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.